EGFR and adenocarcinoma: Based on clinical trials showing improvement of progression‐free survival (PFS) following treatment with first‐ and second‐generation EGFR tyrosine kinase inhibitors (TKIs), EGFR TKIs have become the first‐line treatment for EGFR mutation‐positive adenocarcinomas.3, 4, 5, 6